Tirzepatide(2023788-19-2)Glycemic control improvement (T2DM)

Tirzepatide is a first-in-class, long-acting dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist utilized for the treatment of type 2 diabetes and chronic weight management. By dual-targeting both incretin pathways, it achieves unprecedented efficacy in glycemic control and metabolic regulation. Tirzepatide enhances insulin secretion in response to elevated blood sugar, improves insulin sensitivity, suppresses glucagon release, and delays gastric emptying. Additionally, its potent action on brain centers regulating appetite leads to profound reductions in food intake and body weight, outperforming selective GLP-1 mono-agonists in clinical trials. It is administered via a weekly subcutaneous injection (marketed under brand names such as Mounjaro and Zepbound).